EULAR 2022 | BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice? | rheumatology.medicinematters.com
Skip to main content

Home

Latest news

Browse topics

Lupus
Rheumatoid arthritis
Spondyloarthropathies
COVID-19
Browse all topics

In focus

Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings

Conferences

ACR Convergence 2022
EULAR 2022 Congress

About us

Medicine Matters Rheumatology
EXTENDED SEARCH
Log in

20-06-2022 | EULAR 2022 | Conference coverage | Video

BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

share
SHARE

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials (3:02).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

25-05-2022 | Bimekizumab | Feature | Article

A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

01-06-2022 | EULAR 2022 | Conference coverage | News

BE MOBILE trials support bimekizumab for the treatment of axSpA

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials
Image Credits